RPL17 and neoplasm: Tumor cells may exacerbate this effect by upregulating ANXA1 and activating related signaling pathways, such as AKT, thereby establishing a negative feedback loop that impedes the efficacy of PD‐1/PD‐L1 blockade therapies.